Susquehanna International Group, LLP Harpoon Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$0.65 - $1.37 $21,989 - $46,347	33,830 Added 168.15%	53,949 $39,000
Q4 2022 Feb 14, 2023	BUY	$0.6 - $1.41 $12,071 - $28,367	20,119 New	20,119 $14,000
Q2 2022 Aug 15, 2022	BUY	$1.78 - $5.02 $25,598 - $72,192	14,381 Added 55.65%	40,223 $77,000
Q1 2022 May 16, 2022	BUY	$3.54 - $8.08 $39,134 - $89,324	11,055 Added 74.76%	25,842 $128,000
Q4 2021 Feb 14, 2022	BUY	$5.69 - $7.83 $24,791 - $34,115	4,357 Added 41.77%	14,787 $112,000
Q3 2021 Nov 15, 2021	SELL	$7.88 - $14.0 $288,549 - $512,652	-36,618 Reduced 77.83%	10,430 $82,000
Q2 2021 Aug 11, 2021	SELL	$13.81 - $23.25 $605,098 - $1.02 Million	-43,816 Reduced 48.22%	47,048 $653,000
Q1 2021 May 17, 2021	BUY	$17.65 - $24.16 $1.17 Million - $1.6 Million	66,359 Added 270.8%	90,864 $1.9 Million
Q4 2020 Feb 16, 2021	BUY	$12.83 - $17.84 $105,783 - $147,090	8,245 Added 50.71%	24,505 $407,000
Q3 2020 Nov 16, 2020	BUY	$11.01 - $18.52 $179,022 - $301,135	16,260 New	16,260 $276,000

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.